Investing.com - Financial Markets Worldwide

Jefferies raises Kiniksa stock price target to $54 on strong Q2 results

Published 29/07/2025, 19:18
Jefferies raises Kiniksa stock price target to $54 on strong Q2 results
KNSA
5.68%

Investing.com - Jefferies raised its price target on Kiniksa Pharmaceuticals (NASDAQ:KNSA) to $54.00 from $45.00 on Tuesday, while maintaining a Buy rating on the stock. The company, currently valued at $2.2 billion, is trading near its 52-week high of $30.69, having gained over 30% in the past six months. According to InvestingPro analysis, the stock is currently fairly valued.

The price target increase follows Kiniksa’s strong second-quarter performance, which the company described as a "beat & raise" quarter that continued momentum from the first quarter of 2025.

Kiniksa has increased its 2025 fiscal year guidance from the previous range of $590-605 million to a new range of $625-640 million, reflecting growth in new and repeat prescribers, improved average duration of treatment, and increased penetration into target populations.

The company reported it has $308 million in cash and expects to remain cash flow positive on an annual basis, according to Jefferies’ research note.

Kiniksa’s monthly KLP-387 development remains on track, with the company aiming for a product launch in 2028-2029.

In other recent news, Kiniksa Pharmaceuticals reported second quarter earnings that exceeded analyst expectations and significantly raised its full-year revenue guidance. The company announced adjusted earnings per share of $0.23, surpassing the analyst estimate of $0.19. Revenue for the quarter reached $156.79 million, beating the consensus estimate of $145.28 million. This represents a 44.4% increase from the $108.6 million reported in the same quarter the previous year. The strong performance was primarily driven by the expanding penetration of its ARCALYST therapy among recurrent pericarditis patients. Additionally, Kiniksa Pharmaceuticals raised its full-year revenue guidance, signaling confidence in continued growth. These developments have caught the attention of investors and analysts alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.